Engineered immune cells take on pancreatic cancer in first human trial
NCT ID NCT07153289
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a new treatment called CD318-CAR-T cells for people with advanced pancreatic cancer that has worsened after standard therapy. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study aims to check if the treatment is safe and feasible, and to get an early look at whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD318-targeted CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced pancreatic cancer, a disease with very few effective therapies.
What could go wrong
This is a very early, first-in-human trial with only 38 participants. CAR-T cell therapy can cause severe side effects like cytokine release syndrome, and it is unknown if it will work against solid tumors like pancreatic cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••